Rifamycins
Severe
Textbook
Reduced elvitegravir concentrations, leading to loss of efficacy.
Avoid coadministration.
Source: G&G 14e · p1245-1266
Drug reference
Elvitegravir
Antiretroviral
Antiretroviral
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
g Management of HIV infection in pregnancy should
FDA category + note
Top interactionssee all 12 →
- RifamycinsSevereTextbookG&G 14e · p1245-1266
- St John S WortSevereTextbookG&G 14e · p1245-1266
- ApalutamideSevereDatabaseDDInter
- CarbamazepineSevereDatabaseDDInter
Mechanism
Elvitegravir is an integrase strand transfer inhibitor (INSTI). It acts by preventing the integration of the reverse-transcribed HIV viral DNA into the host cell's genome. This inhibition blocks a critical step in the HIV life cycle, thereby hindering viral replication.
Indications
HIV infectionHIV-1 and HIV-2 infection in HIV-infected adults and children >12 years of age (as part of coformulations)
Dosing
- Adult
- on and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant. This advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland or a list price that is equivalent or lower. l MEDICINAL FORMS regimen is abacavir p. 684 and lamivudine p. 689. The third drug of choice is either ritonavir p.…
Pharmacokinetics
Half-life
12.9
Protein binding
99%
Metabolism
CYP3A4 (major), UGT1A1/3 (minor)
Excretion
6.7% (renal, unchanged)
Side effects
Common
nauseadiarrhea
Pregnancy & lactation
Pregnancy
g Management of HIV infection in pregnancy should
Drug interactions
St John S Wort
Severe
Textbook
Reduced elvitegravir concentrations, leading to loss of efficacy.
Avoid coadministration.
Source: G&G 14e · p1245-1266
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Enzalutamide
Severe
Database
Clinical effect not specified
Source: DDInter
Erdafitinib
Severe
Database
Clinical effect not specified
Source: DDInter
Fosphenytoin
Severe
Database
Clinical effect not specified
Source: DDInter
Lumacaftor
Severe
Database
Clinical effect not specified
Source: DDInter
Mitotane
Severe
Database
Clinical effect not specified
Source: DDInter
Phenobarbital
Severe
Database
Clinical effect not specified
Source: DDInter
Phenytoin
Severe
Database
Clinical effect not specified
Source: DDInter
Primidone
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Antiretroviral therapy for HIV
NACO · Infectious Diseases · 2018
Skin and soft tissue infections
IDSA · Infectious Diseases · 2010
Hepatitis B — chronic infection
EASL · Gastroenterology · 2025
Urinary tract infection
EAU · Urology · 2024
Childhood pneumonia and respiratory infection
MOHFW · Paediatrics · 2021
Other Antiretroviral drugs
Ask House about Elvitegravir
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team